- Home
- NMG vs SGMO Comparison
NMG vs SGMO Comparison
Compare NMG & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMG
- SGMO
- Stock Information
- Founded
- NMG 2011
- SGMO 1995
- Country
- NMG Canada
- SGMO United States
- Employees
- NMG N/A
- SGMO N/A
- Industry
- NMG Other Metals and Minerals
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NMG Basic Materials
- SGMO Health Care
- Exchange
- NMG Nasdaq
- SGMO Nasdaq
- Market Cap
- NMG 175.6M
- SGMO 180.5M
- IPO Year
- NMG 2017
- SGMO 2000
- Fundamental
- Price
- NMG $1.25
- SGMO $1.96
- Analyst Decision
- NMG Strong Buy
- SGMO Buy
- Analyst Count
- NMG 1
- SGMO 3
- Target Price
- NMG $3.00
- SGMO $7.00
- AVG Volume (30 Days)
- NMG 42.7K
- SGMO 11.1M
- Earning Date
- NMG 11-14-2024
- SGMO 11-12-2024
- Dividend Yield
- NMG N/A
- SGMO N/A
- EPS Growth
- NMG N/A
- SGMO N/A
- EPS
- NMG N/A
- SGMO N/A
- Revenue
- NMG N/A
- SGMO $52,291,000.00
- Revenue This Year
- NMG N/A
- SGMO N/A
- Revenue Next Year
- NMG N/A
- SGMO $71.79
- P/E Ratio
- NMG N/A
- SGMO N/A
- Revenue Growth
- NMG N/A
- SGMO N/A
- 52 Week Low
- NMG $1.23
- SGMO $0.30
- 52 Week High
- NMG $3.13
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- NMG 31.03
- SGMO 51.89
- Support Level
- NMG $1.25
- SGMO $1.82
- Resistance Level
- NMG $1.33
- SGMO $2.11
- Average True Range (ATR)
- NMG 0.06
- SGMO 0.38
- MACD
- NMG -0.01
- SGMO -0.10
- Stochastic Oscillator
- NMG 8.37
- SGMO 16.44
About NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.